Kineta to Present Preclinical Data on VISTA Blocking KVA12123 at Immuno US 2023
SEATTLE, Oct. 09, 2023 -- Kineta, Inc. (Nasdaq: KA), a clinical-stage biotechnology company focused on the development of novel immunotherapies in oncology that address cancer immune resistanc ...